3rd October 2018: Cancer care in the South of England took a significant step forward today with the opening of the Rutherford Cancer Centre Thames Valley.
21st August 2018: A new chapter in the provision of advanced cancer care in the North-East of England has started with the official opening of the Rutherford Cancer Centre North East.
8th August 2018: The provision of advanced cancer treatment in the South of England passed a key milestone today with the arrival of the first high energy proton beam therapy system in the region.
7th August 2018: The first patient to be treated with high energy proton beam therapy for breast cancer in the UK commenced treatment this week at the Rutherford Cancer Centre South Wales.
11th April 2018: Proton Partners International announced today it has treated the first patient in the UK with high energy proton beam therapy.
20th March 2018: Proton Partners International has been granted formal technical and regulatory approval from Healthcare Inspectorate Wales to begin treating patients with proton beam therapy at its Rutherford Cancer Centre in Wales.
12th March 2018: IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed three new contracts with Proton Partners International, to install three Proteus®ONE* compact proton therapy solutions across the UK.
7th March 2018: Wales has shown ‘outstanding’ vision in helping to develop innovative proton beam therapy services for cancer patients.
22nd February 2018: Proton Partners International and Ion Beam Applications (IBA) Group, the world’s leading developers of high energy proton beam therapy centres and systems, have officially completed testing on the UK’s first high energy proton beam machine, the Proteus®ONE.
More precise imaging methods and advances in information technology has increased the accuracy of radiation delivery to tumours, according to chief medical officer of Proton Partners International Professor Karol Sikora.
Speaking at BIT’s Annual World Cancer Congress 2017 in Barcelona today, Professor Sikora told delegates that radiotherapy delivery has become increasingly accurate over the last two decades because of computer software originally designed for military purposes.
Advances in accuracy means that there has been a marked reduction in the long-term side effects of radiotherapy due to the ability to reduce collateral damage to normal tissue. The increasing availability of proton beam therapy, a form of radiotherapy, has also further refined the precision of delivery as protons can be controlled to stop at a defined point in the body.
Professor Sikora said: “Around 50% of cancer patients are treated with radiotherapy and we can estimate that around 10% of these patients would actually be treated more effectively with proton beam therapy. In Britain, this would mean a requirement for 18 centres.
“The range of published estimates for the utilisation of protons in radical radiotherapy ranges from 1%, in line with the NHS, to 20%, in the US, however most European countries are planning for at least 10% of radiotherapy to be delivered by protons.
“Proton beam therapy cannot be used in all cases, but it is particularly useful in situations where a tumour is in juxtaposition with a critically radio-sensitive normal structure, for example the spinal cord in a child with a neurological tumour.
“The UK is one of the last counties in Western Europe to have a high-energy proton treatment facility, the first of which will be at The Rutherford Cancer Centre, South Wales, which is currently being built by Proton Partners International. We’re also building a centre in the North West, the North East and in the Thames Valley to ensure that proton beam therapy, in addition to conventional cancer treatments, are available to more patients across the UK.
“Unless there is an urgent policy change the overall quality of British radiotherapy will fall below European levels by 2020. It’s important that we work together to ensure that cancer patients are given the care they deserve.”